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Abstract
Cardiopulmonary exercise test (CPET) has been gaining 
importance as a method of functional assessment in Brazil and 
worldwide. In its most frequent applications, CPET consists 
in applying a gradually increasing intensity exercise until 
exhaustion or until the appearance of limiting symptoms and/
or signs. The following parameters are measured: ventilation; 
oxygen consumption (VO2); carbon dioxide production 
(VCO2); and the other variables of conventional exercise 
testing. In addition, in specific situations, pulse oximetry and 
flow-volume loops during and after exertion are measured. 
The CPET provides joint data analysis that allows complete 
assessment of the cardiovascular, respiratory, muscular and 
metabolic systems during exertion, being considered gold 
standard for cardiorespiratory functional assessment.1-6 
The CPET allows defining mechanisms related to 
low functional capacity that can cause symptoms, such 
as dyspnea, and correlate them with changes in the 
cardiovascular, pulmonary and skeletal muscle systems. 
Furthermore, it can be used to provide the prognostic 
assessment of patients with heart or lung diseases, and in the 
preoperative period, in addition to aiding in a more careful 
exercise prescription to healthy subjects, athletes and patients 
with heart or lung diseases.
Similarly to CPET clinical use, its research also increases, 
with the publication of several scientific contributions from 
Brazilian researchers in high-impact journals. 
Therefore, this study aimed at providing a comprehensive 
review on the applicability of CPET to different clinical 
situations, in addition to serving as a practical guide for the 
interpretation of that test.
Major variables and their meanings 
Oxygen consumption (VO2): is the volume of O2 extracted 
from the air inhaled during pulmonary ventilation in a period 
of time. It is usually expressed in mL.min-1 or L.min-1 (STPD). 
In practice, maximum VO2 (VO2 max) is defined as the 
highest value reached, despite progressive increase of the 
load applied, with the development of a plateau in the VO2 
curve during an incremental exercise test. When no plateau 
can be identified, the highest value obtained at the end of an 
exhausting exercise is characterized as peak VO2, which, in 
practice, is used as VO2 max. Mean values at intervals of 10 
to 60 seconds should be measured depending on the protocol 
(short-interval means for protocols with short stages and 
longer-interval means for protocols with longer stages). The 
response is influenced by a central mechanism (cardiovascular 
and/or pulmonary) and peripheral function (skeletal muscle).1-6 
The normal values depend on several factors, such as: age, sex, 
weight, height, physical activity level, genetic variability and 
ethnicity. Different equations to predict the normal values of 
VO2 max or peak VO2 have been determined from different 
populations. Although the equation proposed by Wasserman 
and Whipp6 is the most frequently used, a national equation7 
seems to be more suitable for Brazilians.
The term ‘peak VO2’ is used as a synonym for VO2 max 
throughout this text. Peak VO2 is considered abnormal when 
below 85% of the predicted value.6 It has been used as a 
universal marker1-3,5 that can broadly reflect disease severity 
in patients with heart failure (HF), pulmonary hypertension, 
hypertrophic cardiomyopathy (HCM), chronic obstructive 
pulmonary disease (COPD) and restrictive pulmonary disease, 
in addition to physical fitness level.1-5,8 The VO2 value measured 
in the first ventilatory threshold (VT1) or anaerobic threshold 
(AT) is determined by the nonlinear increase of pulmonary 
ventilation (VE) in relation to VO2. From the physiological 
viewpoint, AT represents the upper limit of workloads during 
exercise, which can be sustained over a prolonged period 
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of time without progressively increasing blood lactate and 
consequent pulmonary hyperventilation.6 Peak VO2 and AT 
values are influenced by genetic predisposition, diseases, 
exercise and aerobic training types. The normal mean AT 
values expected for adults are around 40% to 65% of peak 
VO2.
6 The AT values are important for the individualized 
prescription of exercise, as well as for the diagnosis of 
anemia, physical unfitness, myopathies and cardiopathies 
in the presence of values lower than the predicted ones.2-6
Pulmonary ventilation (VE): expressed as liters per 
minute, is the volume of air moved in and out of the lungs. It 
is determined as the product of respiratory rate by the volume 
of air exhaled at every cycle (tidal volume). At rest, 7 to 9 L/
min are ventilated, but in athletes that value can reach 200 L/
min at maximal exertion.6 Ventilation increases continuously 
during progressive effort on CPET and undergoes additional 
increases influenced by the anaerobic metabolism resulting 
from the accumulation of lactic acid, well defined as the first 
and second ventilatory thresholds. Periodic (or oscillatory) 
ventilation is defined as the resting oscillatory pattern that 
persists in ≥ 60% of the effort with an amplitude ≥ 15% as 
compared to mean resting values.9 It reflects disease severity 
and relates to worse prognosis in patients with HF.3-5
Respiratory coefficient or respiratory exchange ratio 
(R): expresses the ratio between CO2 production and O2 
consumption (VCO2/VO2). It is currently the best non-invasive 
indicator of maximal or quasi-maximal exercise intensity. 
Values above 1.0 can reflect intense exercise, but those 
≥ 1.10 are those searched on CPET, and have been accepted 
as a parameter of exhaustion or quasi-exhaustion.3,7
Ventilatory equivalents for oxygen (VE/VO2) and 
for carbon dioxide (VE/VCO2): are the ratios between 
pulmonary ventilation and O2 consumption (VE/VO2) or CO2 
production (VE/VCO2). Both decline from rest to submaximal 
exercise intensities, with VE/VO2 reaching minimum values 
before AT, when its progressive increase occurs, caused by 
the increase in ventilation to eliminate extra CO2 production. 
That results in lactate buffering by blood bicarbonate.6 Later, 
VE/VCO2 increases (respiratory compensation point - RCP, or 
second ventilatory threshold - VT2), resulting from ventilatory 
increase (compensatory respiratory alkalosis) in response to 
blood pH reduction due to the progressive accumulation of 
lactic acid at muscle level.6 The VE/VO2 reflects the ventilatory 
need for a certain O2 consumption level, being, thus, an 
index of ventilatory efficiency. Patients with inadequate ratio 
between pulmonary ventilation and pulmonary perfusion 
(increased physiological dead space) ventilate inefficiently 
and have high VE/VO2 values (pulmonary disease and HF).
6 
Peak values above 50 have been useful to diagnose patients 
suspected of having mitochondrial myopathy.10 On the other 
hand, VE/VCO2 represents the ventilatory need to eliminate 
a certain amount of CO2 produced by active tissues, being 
influenced by partial pressure of carbon dioxide (PaCO2). 
In addition, VE/VCO2 slope is the relationship between 
VE, plotted in the Y axis, and VCO2, in the X axis, both 
measured as L/min. The VE/VCO2 slope can be determined 
in submaximal tests.11 It relates to changes in the ventilation-
perfusion relationship or hyperventilation. The VE/VCO2 
slope reflects the severity and prognosis of patients with 
HF, pulmonary hypertension, HCM, COPD and restrictive 
pulmonary disease.1,3-5,8,11,12
End-tidal CO2 partial pressure (PETCO2): reflects 
ventilation–perfusion within the pulmonary system, and, 
indirectly, cardiac function.6 Its value ranges from 36 to 42 
mmHg, with 3- to 8-mmHg elevations during moderate 
intensity exercise, reaching a maximal value with subsequent 
drop, due to VE increase, characterizing RCP.1 Abnormal values 
can represent disease severity in patients with HF, HCM, 
pulmonary hypertension, COPD and restrictive pulmonary 
disease.3-6,8,12
Oxygen pulse (O2 pulse): is the ratio between VO2 
(mLO2/min) and heart rate (HR - bpm). Its meaning is better 
understood by observing the Fick equation: VO2 = HR 
x systolic volume (SV) x arteriovenous oxygen difference 
[(A-V)O2 diff]. Considering that, in many clinical situations, 
(A-V)O2 diff does not substantially change in incremental 
exercise, O2 pulse represents SV, and, in a way, left ventricular 
performance. Thus, VO2 ≅ HR x SV or VO2/HR ≅ SV. Under 
certain circumstances, the morphological analysis of its curve 
aids in the diagnosis of ventricular dysfunction and important 
effort-induced myocardial ischemia.1,3-6
Breathing reserve (VE/MVV): represents the ratio between 
maximal ventilation during exercise (VE) and maximum 
voluntary ventilation (MVV) at rest, both variables in L/min. 
Equations to predict MVV can be used (forced expiratory 
volume in the first second – FEV1 x 40), although it can be 
measured directly on pre-test spirometry. Normal values 
are greater than 0.20. However, in both athletes and those 
performing strenuous exercises, a higher fraction of breathing 
reserve can be physiologically used. It is useful in the differential 
diagnosis of dyspnea related to pulmonary mechanism.6 
ΔVO2/ΔWR Relationship: relationship between VO2 (Y 
axis in mL.min-1) and workload (X axis in Watts), measured 
only during exercise on a cycle ergometer with ramp protocol, 
whose value is progressively and linearly incremented until 
maximal effort. It is useful in the diagnosis of patients suspected 
of having myocardial ischemia with left ventricular dysfunction 
on exertion. Its normal value for adults is 9 mL.min-1.W-1 (the 
lowest limit being 8.6 mL.min-1.W-1).
Other variables: the minimum VE/VO2 value is the 
cardiorespiratory optimal point (COP).13 It is a submaximal 
variable that reflects the best integration between the respiratory 
and cardiovascular systems. Although it is easy to obtain, further 
studies are required to determine its clinical applicability and 
prognostic meaning. Oxygen uptake efficiency slope (OUES) 
was widely studied, being measured by the relationship 
between VO2 and the logarithmic transformation (base 10) of 
VE. The OUES provides information on the severity of HF.14 
Similarly to VE/VCO2 slope, it does not require a maximal test. 
T1/2VO2 is the time necessary for a 50% drop in VO2 measured 
at peak exercise (from the beginning of recovery) until the 
third minute of recovery. It decreases with physical training 
and its increase is negatively associated with the prognosis of 
HF patients.15 Circulatory power is the product of peak systolic 
blood pressure (SBP) by peak VO2, while ventilatory power is 
peak SBP divided by VE/VCO2 slope. Both have prognostic value 
in HF.16 Finally, the association of CPET with measurements of 
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cardiac output and SV, by use of non-invasive hemodynamic 
analysis (impedance cardiography - ICG), can provide variables, 
such as ΔQ/ΔVO2 slope to assess coronary artery disease (CAD), 
HF and some myopathies.10
Functional assessment and CPET-based aerobic exercise 
prescription 
The CPET is considered the best method to assess aerobic 
performance, and, mainly, to support aerobic exercise 
prescription.17,18 Considered class IIa indication - optimized 
prescription of exercise to healthy individuals, individuals with 
heart or lung diseases entering a program of regular exercise - 
and class IIb indication – athletes -,1 it is still rarely used with 
such purposes by clinical cardiologists.  
By use of the joint analysis of exhaled gases, work and/
or exertion performed and the behavior of hemodynamic 
variables, mainly HR, a more comprehensive functional 
assessment can be obtained. Thus, a more precise and 
individualized program of aerobic exercise can be outlined. 
Apparently healthy individuals who engage in moderate- 
to high-intensity aerobic practice can benefit from CPET 
regarding exercise prescription and performance assessment.18 
For individuals with heart diseases and high-performance 
athletes, such benefits have been widely established. 
Prescription errors, both insufficiency and excess, in such 
individuals can have a negative impact on the results expected 
from a training program. 
Briefly, for the prescription of aerobic exercises, the most 
relevant data obtained from CPET are HR and exercise 
intensity at which the ventilatory thresholds occur, especially, 
AT or VT1.19 The exercise intensity at which VT1 occurs 
characterizes the highest submaximal level tolerated by 
a certain individual for long time periods. Because that 
exercise intensity varies even between two individuals with 
identical maximal functional capacity (and even with similar 
maximal VO2 values measured), its precise determination via 
CPET enhances and refines the quality of aerobic exercise 
prescription. In practical terms, HR values in different points 
of maximal CPET are used to establish the bases for a more 
objective prescription. More often, the following values 
are considered: HR at rest with the individual lying down 
(resting HR), maximal HR (HRmax), HR at AT, HR at RCP, 
and HR at the ‘R = 1’ point. Traditionally, exercises have 
been prescribed based on the intensity related to HR, but the 
workload related to thresholds and maximal effort can also 
be used.1,20 When the objective is to train up to a moderate 
subjective intensity that can be sustained for long periods, we 
set the limit at the AT. Between the AT and RCP, the exercise 
intensity is higher, but usually still tolerated for prolonged 
periods, with wide individual variations. Finally, the training 
can be performed above the RCP, with very intense and 
much more difficult to sustain exercises, which can be of 
the interval type (alternating resting periods with some type 
of mild-to-moderate intensity exercise).20 
There are numerous protocols that can be used for both 
healthy individuals and those with diverse patologies.21 These 
protocols are used to prescribe steady-state aerobic exercise 
(walking or running) or interval exercise, with an important 
component of “anaerobic” exercise, alternating rhythms 
and intensities (alternate walking and running, up and down 
walking and cycling, ball sports and spinning classes). 
However, the quality of that prescription, based on HR 
derived from CPET, depends on some factors. It is convenient 
that CPET be performed with a ramp protocol, minimum 
duration of eight minutes, on an ergometer more similar to 
the aerobic exercise that will be prescribed (cycle ergometer 
for cyclers, treadmill for runners). Longer protocols tend to 
allow greater differentiation and precision in identifying the 
exercise intensity that corresponds to the thresholds. It is 
worth noting that data collected during a CPET performed 
in an air-conditioned room can differ from those obtained 
during a walk or cycling or even a long running (more than 
45 minutes) at open air locations and under more adverse 
climate conditions, in which there may be a cardiovascular 
drift22 phenomenon, characterized by a progressive increase 
of HR, instead of remaining in steady-state, despite of a 
constant intensity of exercise. However, for patients using 
HR-controlling devices or on regular use of medications 
with negative chronotropic action, specific care should be 
taken so that the HR-based prescription obtained on CPET 
can remain valid. The most obvious case is that of patients 
on beta-blockers on a single daily dose, which make HR 
during exercise vary according to the time interval between 
medication administration and exercise performance.23 
To minimize that chronopharmacological effect, such patients 
should undergo CPET at the time closest to that of regular 
exercise. In patients with pacemakers, resynchronization 
devices and atrial fibrillation, the HR measured by these HR 
sensors is inaccurate. For those individuals and some athletes 
whose training intensity is based on load or velocity, exercise 
can be prescribed based on velocities or loads relative to 
thresholds. Some studies have suggested that the load relative 
to ‘R = 1’ bears the best correlation with maximal exertion 
in metabolic balance.24
Finally, other potentially relevant variables can be obtained 
via exhaled breath analysis, including some that do not require 
maximal exertion, such as mechanical efficiency analysis 
and COP,13 which widens the CPET value for prescription of 
primarily aerobic exercises. 
CPET in heart failure
Chronic heart failure (CHF) is a systemic syndrome, and 
reduced functional capacity is one of its main features. The 
cardiovascular deficit has a direct influence on other organs and 
systems, such as the pulmonary, renal and skeletal muscular 
ones. CPET is considered “gold standard” for the functional 
assessment of patients with CHF, propitiating diagnostic 
and prognostic data derived from direct measurement 
of VO2, VCO2 and VE. In addition, the variables VE/VO2, 
VE/CO2, VCO2/VO2 and R, as well as the metabolic points 
AT and RCT, are useful parameters to indicate accurately the 
maximal aerobic capacity, to quantify functional restriction, to 
measure the response to drug therapy and to guide physical 
training prescription.
The Brazilian Society of Cardiology guidelines for the 
management of patients with CHF present CPET as class I 
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indication in the assessment of both heart transplantation 
candidates and dyspnea mechanisms. The use of CPET is 
class II indication for exercise prescription, and to assess the 
severity, prognosis and responses to therapeutic interventions 
in CHF.25,26
The response to CPET of a patient with CHF is characterized 
by: reduced VO2, AT < 40% of the predicted VO2 max, 
O2 pulse < 85% and as a plateau, increased VE/VCO2, 
reduced OUES, wide breathing reserve and usually normal 
O2 saturation.
2 Peak VO2 is the specific and direct measure 
of functional capacity. Several studies have shown its 
independent prognostic capacity in CHF. According to the 
Brazilian guidelines for heart transplantation, a peak VO2 lower 
than 10 mL.kg-1.min-1 is class I indication for that procedure, 
while a peak VO2 below 12 mL.kg
-1.min-1 (patients on beta-
blocker) or below 14 mL.kg-1.min-1, is class IIa indication, 
particularly for those with other criteria of worse prognosis 
(VE/VCO2 slope > 35).27  Weber et al.28 have proposed a 
classification for peak VO2 results: class A = VO2 > 20 mL.kg
-1.
min-1; class B = VO2 16-20 mL.kg
-1.min-1; class C = VO2 10-
15 mL.kg-1.min-1; and class D = VO2 < 10 mL.kg
-1.min-1.  It 
is worth noting that, for peak VO2 value to have prognostic 
accuracy, the test has to meet the requirements of a maximal 
test (proposed for HF: R > 1.05, at least).
 Other important variables measured via CPET that 
add independent prognostic value for patients with CHF 
are: VE/VCO2 slope, OUES, T1/2VO2, HR recovery in the first 
post-exertion minute, presence of periodic ventilation, and 
PETCO2 and O2 pulse behaviors.
Chua et al.,29 assessing patients with CHF using CPET, 
have observed those with VE/VCO2 slope > 34 were at 
higher risk for hospitalization due to decompensation, and 
for death. Other authors,30-32 assessing the prognostic value 
of VE/VCO2 slope in CHF, have shown it to be a variable with 
excellent  independent value, even higher than that of peak 
VO2, and important to patients who reach only submaximal 
exertion. In a population with CHF due to Chagas disease, 
Ritt et al.33 have reported that the best cutoff point for 
worse prognosis was VE/VCO2 slope > 32.5, thus earlier 
than those reported by studies on other etiologies. Arena et 
al.34 have published the following ventilatory classes based 
on VE/VCO2 slope values: class I, VE/VCO2 ≤ 29.9; class 
II, 30-35.9; class III, 36-44.9; class IV, ≥ 45. In 2 years, 
event-free survivals (death, transplantation or implantation 
of ventricular assistance device) for classes I-IV were 97.2%, 
85.2%, 72.3% and 44.2%, respectively (P < 0.0001). 
Assessing a population of patients via CPET for heart 
transplantation, Ferreira et al.35 have found a VE/CO2 slope 
cutoff point of ≥ 43 as ideal to determine the indication 
for heart transplantation. The use of VE/VCO2 slope as a 
criterion for selection of candidates for transplantation 
could reclassify correctly 18.3% more patients than the 
classic peak-VO2-based criteria (p < 0.001).
35
In addition, OUES has an independent prognostic value. 
Initially, Baba et al.36 have described that variable behavior, 
whose cutoff point and independent prognostic value were 
subsequently assessed by other authors. A cutoff point 
< 1.47 L/min determines a group with more severe CHF.37,14
T1/2VO2 is identified in patients with CHF. Studying 
patients with VO2 ≥ 15, between 10.1 and 14.9, and 
≤ 10 mL.kg-1.min-1, Groote et al.38 have reported T1/2VO2 
values of 108 ± 44.6, 137 ± 58.7, and 176 ± 75 seconds, 
respectively.38 In patients with no heart disease, T1/2VO2 is 
usually < 90 seconds.39
The kinetics of HR recovery (HRR) is a well-established 
prognostic marker in patients with CAD,40 related to changes 
in post-exertion autonomic balance. In CHF, it is also an 
independent factor of mortality, even in patients on beta-
blockers.41 The cutoff point established for that population 
was ≤ 16 bpm in an active recovery protocol (hazard ratio: 
4.6; 95%CI: 2.8–7.5; p < 0.001). Its clinical usefulness has 
been assessed for heart transplantation indication in patients 
in the intermediary zone of peak VO2 (VO2 10.1-13.9 mL.kg
-1.
min-1), in whom, the HRR analysis aggregated value to peak 
VO2 and VE/VCO2 slope. The prognosis of patients with altered 
HRR and VE/VCO2 slope was comparable to that of those with 
VO2 < 10 mL.kg
-1.min-1.42
Wide oscillations in ventilation during exertion relates 
to cardiovascular events and death in patients with CHF. 
That pattern, analogous to the Cheyne-Stokes respiration, 
was named periodic ventilation. The occurrence of periodic 
ventilation during exertion (characterized by an amplitude 
variation > 5 L/min for at least three cycles) was related to 
an up to three-fold higher mortality in patients with CHF 
(hazard ratio: 2.97; 95%CI: 1.34 – 6.54; p < 0.007).9,43,44 The 
presence of periodic ventilation increased the risk of patients 
with reduced peak VO2 and elevated VE/VCO2 slope.
45
Another index that reflects the dynamics of pulmonary 
changes and CO2 diffusion at alveolar level is PETCO2 at 
rest. Mean values < 33 mmHg after 2 minutes at rest were 
independently correlated with worse prognosis and greater 
mortality in CHF (hazard ratio: 2.17; 95%CI: 1.48-3.19; 
p < 0.001).46
O2 pulse can be assessed regarding its absolute value 
and its behavior during exertion. A plateau is usually related 
to an insufficient increase in SV on exertion. An O2 pulse 
< 85% of the predicted value correlates independently 
with major cardiovascular events in CHF. Among patients 
with peak VO2 < 14.3 mL.kg
-1.min-1 and O2 pulse < 85% 
of the predicted values, mortality was greater than among 
those with only one of those parameters altered (hazard 
ratio: 4.76 versus 2.31, respectively). O2 pulse could also 
reclassify the risk of patients into intermediate zone of peak 
VO2 for transplantation (10-14 mL.kg
-1.min-1). Patients in 
the O2 pulse < 85% zone had mortality similar to those 
with VO2 < 10 mL.kg
-1.min-1.47
Each CPET variable correlates with the interaction of HF 
with another organ or system. Thus, the joint analysis of those 
variables can better stratify the risk of those patients. The 
CPET variables can be combined into risk scores in CHF. Levy 
et al. have shown that the addition of VE/VCO2 slope data 
to Seattle Heart Failure Model could improve the prognostic 
ability of that score, reclassifying 40% of the patients into a 
more appropriate risk category (p = 0.002).48 
To determine the prognostic significance of CPET in CHF, 
Cahalin et al. have conducted a meta-analysis of studies 
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published until 2013 and calculated the odds ratios (OR) 
of each prognostic variable. The OR of the main prognostic 
variables assessed (peak VO2, VE/VCO2 slope, OUES and 
periodic ventilation) were 4.10 (CI: 3.16-5.33), 5.40 (CI: 
4.17–6.99), 8.08 (CI: 4.19–15.58) and 5.48 (CI: 3.82–7.86), 
respectively.49
For those not dealing with CPET on a daily basis, the 
assessment of each variable can be unpractical. Myers et al.50 have 
developed a score that combines the information of the main 
CPET variables into a number. The points are attributed as follows: 
VE/VCO2 slope ≥ 34 - 7 points; HRR ≤ 16 bpm - 5 points; OUES 
≤ 1.4 - 3 points; PETCO2 < 33 mmHg - 3 points; peak VO2 ≤ 14 
mL.kg−1.min−1 - 2 points. The score ranges from 0 to 20, 0-5 being 
the reference. The others correlated in an increasing manner with 
the risk of death/transplantation or implantation of ventricular 
assistance device: 6-10 (hazard ratio: 2.74, 95%CI: 2.16–3.48; 
p < 0.001), 11-15 (hazard ratio: 4.6, 95%CI: 3.55–5.98; p < 
0.001) and > 15 (hazard ratio: 9.25, 95%CI: 5.75–14.88; p < 
0.001). In three years, the mortality of patients with score >15 
was 12.2%, in comparison to 1.2% in those with score < 5. A 
recent analysis51 applied that score to class B patients according 
to Weber heart failure classification (analogous to NYHA class 
II). In the three-year follow-up, patients with score ≥ 10 had an 
event-free survival equivalent to that of Weber class C patients, 
and those with score < 10 had a prognosis equivalent to that of 
Weber class A patients.
The CPET plays a preponderant role in the assessment 
of patients with CHF, not only regarding the selection of 
candidates for transplantation, but also to determine the 
prognosis and help with the therapeutic decision. Figure 1 
shows a stratification strategy that combines those variables.
CPET to assess myocardial ischemia
CPET can help to assess myocardial ischemia in patients 
with suspected CAD, a clinical condition where a significant 
ischemic load, during exercise, is expected to negatively 
influence systolic myocardial performance.1 During 
incremental exercise, the myocardial unbalance between O2 
offer and demand triggers a sequence of metabolic changes 
that can ultimately lead to the insufficient physiological 
elevation of SV. On CPET, this is observed as a depressed, in 
plateau or declining shape curve of O2 pulse.
Three CPET variables are indicated to assess the presence 
and severity of myocardial ischemia: 1) O2 pulse; 2) VO2 curve 
and elevation; and 3) relationship between VO2 variation 
and load variation, in watts, in this case, exclusively, on 
cycle ergometer.52
Oxygen pulse and oxygen consumption curve
Usually, (A-V)O2 diff tends to remain constant during 
incremental exertion, except for rare cases of anemias, 
Figure 1 – Risk stratification based on CPET results from patients with CHF (Modified from Ribeiro JP, Stein R, Chiappa GR. J Cardiopulm Rehabil. 2006 Mar-
Apr;26(2):63-71). CPET: cardiopulmonary exercise test; VO2: oxygen consumption; R: respiratory exchange ratio; VE/VCO2 slope: ratio between pulmonary ventilation 
and carbon dioxide production; PETCO2: extrapolated end-tidal carbon dioxide tension; T1/2: time necessary for a post-exertion 50% drop in VO2 measured; OUES: 
oxygen uptake efficiency slope; HRR: heart rate recovery.
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hemoglobinopathies, some congenital heart diseases and 
COPD, in which there is a significant drop in peripheral 
oxygen saturation. Except for those clinical conditions, one 
can infer that SV behavior during incremental exercise is 
reflected by the equation: VO2/HR = SV. The VO2/HR ratio, 
called “oxygen pulse” and measured in milliliters per beat, 
reflects the O2 volume ejected into the aorta at every systole. 
Likewise, SV, also measured in milliliters per beat, reveals the 
blood volume ejected into the aorta at every systole. Thus, 
those two variables, despite being numerically different, reflect 
left ventricular hemodynamic behavior during CPET.
The analysis of the VO2/HR curve as a function of time, 
which should have the increasing morphology of a parabola, 
is as important as the numerical O2 pulse value during the 
incremental phase of CPET. The identification of a curve with 
a plateau or decline indicates a reduction in O2 pulse and 
SV during exercise, and can indicate myocardial ischemia53 
(Figure 2). It is worth noting that other clinical conditions can 
cause similar changes, such as ventricular dysfunctions due 
to non-ischemic cardiomyopathies, providing prognostic 
information on HF with reduced ejection fraction,3 and 
obstructive valve heart diseases. In the presence of severe 
chronotropic changes, artificial electric stimulation and 
arrhythmias, such as atrial fibrillation, O2 pulse analysis 
becomes compromised and inaccurate. 
ΔVO2/ΔWR Ratio (Watts)
To every increase in load imposed during CPET, a similar 
increase in VO2 is expected. Normally, a 1-Watt increment 
in workload should correspond to a 10 mL.min-1-increase 
in absolute VO2. The loss of this linear relationship, with a 
reduction of slope often to less than 5 mL.min-1.Watt-1, despite 
the increase in exercise intensity during CPET, contributes to 
the diagnosis of myocardial ischemia52 (Figure 3).
It is worth noting that the changes suggestive of ischemia 
on CPET become more evident as ischemia severity increases. 
The CPET variables should be analyzed in light of the pre-test 
clinical suspicion. CPET can be indicated for functional 
assessment of patients with established CAD, as well as for 
the investigation of myocardial ischemia diagnosis, mainly in 
the following conditions: 
 1. When there is moderate to high pre-test likelihood of 
myocardial ischemia;
 2. To increase diagnostic accuracy of myocardial ischemia, 
when, on CPET, there is clinical, hemodynamic or 
electrocardiographic change, hindering the diagnosis via 
conventional exercise test;
 3. In the presence of a large ischemic myocardial area, 
hindering left ventricular function due to SV reduction 
during exercise;
 4. For follow-up assessment after percutaneous or surgical 
revascularization;
 5. Similarly to other clinical conditions, CPET can be 
recommended to assess the prognosis of patients with 
CAD, with or without evidence of ischemia, by using other 
variables usually used for that purpose, such as VE/VCO2 
slope, peak VO2, OUES, periodic ventilation and T1/2VO2, 
Figure 2 – Cardiopulmonary exercise test in the pre-rehabilitation assessment of a 57-year-old hypertensive, diabetic, overweight male patient with three-vessel coronary 
disease, who refused to undergo myocardial revascularization surgery eight years earlier. A) evident drop in oxygen pulse. B) early plateau of oxygen consumption. Both 
changes (A and B) were due to ischemic depression of the ST segment (evident in A), followed by progressive chest pain.
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Figure 3 – The ΔVO2/ΔWR relationship around 10mL.min.Watts suddenly reduces, despite the exercise intensity increase. This loss of linear relationship could indicate 
the presence of myocardial ischemia by use of CPET performed on a cycle ergometer (modified from reference 52).
in addition to other CPET variables that wait for more solid 
studies.6,54-57
CPET in the differential diagnosis of dyspnea
Dyspnea is a common symptom in several clinical 
situations, characterized by the perception of respiratory 
difficulty or discomfort. Its pathophysiology is complex, 
involving neuro-humoral and mechanical mechanisms. 
From the practical viewpoint, the differential diagnosis can 
be classified into four categories: cardiac, pulmonary, mixed 
cardiopulmonary, and non-cardiopulmonary.58,59
The use of CPET for dyspnea assessment can be divided 
into two settings - patients with dyspnea without an established 
diagnosis and patients with multiple possible causes - in 
whom the test is useful to determine which mechanism 
prevails and causes symptoms. The dyspnea, whose cause 
cannot be elucidated via history, physical examination and 
complementary tests at rest, should be better assessed by 
using CPET. By use of joint analysis, from rest to maximal 
exertion, the cardiovascular, respiratory and peripheral 
metabolism responses can provide information on the dyspnea 
mechanism. Because of its low cost, CPET can be indicated 
early in the investigative hierarchy of dyspnea assessment, 
serving to guide other complementary tests, when required, for 
therapeutic management and prognostic assessment (Table 1).
Studies on the clinical value of CPET in patients with 
chronic dyspnea (more than 1 month) of undetermined origin 
or dyspnea of multiple causes have evidenced practical use: to 
differentiate dyspnea of cardiocirculatory primary origin from 
dyspnea of pulmonary ventilatory etiology or that related to 
problems in the ventilation-perfusion binomial; to quantify the 
different mechanisms of multiple-cause dyspnea; to identify 
an unsuspected or underestimated circulatory component; 
and to identify a psychogenic or simulation component.60,61
The differential diagnosis of those pathologies requires 
pragmatic interpretation of CPET data.62 The first step is to 
assess peak VO2 and to determine the percentage of the 
predicted value achieved. Pulmonary, cardiovascular and 
metabolic diseases or physical unfitness can account for VO2 
reduction. Then, breathing reserve should be assessed, and, 
when low, it can identify underlying pulmonary disease. 
Breathing reserve lower than 20% is found in pulmonary 
diseases; however, as already described, highly-trained 
individuals or those in situations of extreme exertion can also 
consume their ventilatory reserve on maximal exertion as a 
compensatory mechanism, but, in such cases, peak VO2 will 
not be significantly reduced.
The following step is the analysis of O2 saturation. A drop 
greater than 4% on peak exertion as compared to resting is 
characteristic of pulmonary limitation. High VE/VCO2 slope 
and PETCO2 < 33 mmHg at rest and/or elevation greater than 
8 mmHg during exertion suggest respiratory mechanisms as 
the cause of dyspnea.3,63
Observation of O2 pulse and ΔVO2/ΔWR ratio can identify 
heart disease, if the curves show plateau or decline, reflecting 
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an inadequate SV to the load imposed.64 However, individuals 
with lung disease and some degree of pulmonary hypertension 
can also develop a plateau of O2 pulse. The combination of 
plateau of O2 pulse with a decrease in O2 saturation, VE/VCO2 
slope > 40 and reduced PETCO2 (< 33 mmHg at rest or < 36 
mmHg at AT) strongly suggests pulmonary hypertension or a 
pathology with pulmonary vascular impairment.3,63,65
Patients with dyspnea due to cardiovascular limitation have 
reduced VO2, early AT, ventilatory inefficiency (high VE/VCO2 
slope), inefficient O2 uptake (reduced OUES), plateau of O2 
pulse or of ΔVO2/ΔWR ratio, with normal ventilatory reserve, 
PETCO2 < 33 mmHg at rest and/or increase < 3 mmHg during 
exertion, in addition to lack of drop in O2 saturation.
3,63
Patients with physical unfitness and anemia have reduced 
VO2 and increased ΔVO2/ΔWR (cycle ergometer), but they 
do not meet the criteria for pulmonary or cardiovascular 
limitation. Extremely physically unfit patients can have 
reduced AT and increased HR/VO2 ratio. On the other hand, 
a low R, despite the sensation of extreme fatigue on BORG 
scale, points to a peripheral mechanism as the cause of 
limitation to exertion. 
Patients with hyperventilation have reduced ventilatory 
efficiency (high VE/VCO2 slope), reduced PETCO2 at AT, 
sudden changes in the ventilatory pattern with phases of 
tachypnea and hypopnea, and extremely increased respiratory 
rate on exertion. Usually, the ventilatory reserve is normal and 
O2 saturation has a physiological behavior. 
Studying 39 patients with asthma of difficult control, 
McNicholl et al. have reported that, in 14 of them, 
the persistent complaint of dyspnea was explained by 
hyperventilation, preventing the undue increase of the dose 
of bronchodilators in those patients.66 In legal situations, 
facing a complaint of dyspnea, the medical expert can have 
difficulty to determine if the symptom is true or to establish an 
effective symptom graduation, and CPET can be used to clarify 
the scenario. To diagnose fake dyspnea by using CPET: the 
patient reports extreme fatigue, asks for exertion interruption 
and shows normal ventilatory reserve, normal O2 saturation 
behavior, AT within the expected range for the maximal VO2 
predicted (40%-60%), but an R compatible with submaximal 
exertion (<1), in addition to apparent chronotropic deficit. 
CPET in pulmonary diseases
Chronic obstructive pulmonary disease
The severity of COPD is determined based on symptoms 
and spirometry results. Pulmonary function tests at rest, 
however, do not accurately predict the grade of intolerance 
to exertion.
64 The inability to increase ventilation to levels 
that allow high gas exchange is one of the mechanisms that 
explain dyspnea on exertion. That phenomenon can be 
observed on CPET and is usually interpreted as ventilatory 
limitation. Although characteristic of obstructive scenarios, 
it can occur in restrictive diseases, such as interstitial 
pulmonary diseases, and in abnormalities of the thoracic 
cage. The criterion that defines ventilatory limitation is 
arguable, but, when the breathing reserve at peak exertion 
is lower than 15%, limitation is considered to occur, 
especially when R is lower than 1.0.
67 
In patients with COPD, peak VO2 continues to be 
the best index of aerobic capacity, as long as patients 
exercise to their limit. However, other aspects should be 
considered when interpreting the CPET of patients with 
COPD. There is a combination of low ventilatory capacity 
and high ventilatory demand, increasing the sensation of 
dyspnea. The perception of lower limb exertion is often 
exaggerated in such patients and can be a limiting factor, 
especially in tests performed on a cycle ergometer.
2 Another 
factor that can significantly contribute to the development 
of unbearable dyspnea during exercise is dynamic 
hyperinflation. With the increase of respiratory flow during 
exercise, the air is held in the lungs, causing a progressive 
increase in residual volume, thus reducing the inspiratory 
capacity (Figure 4). That frequently occurs together with a 
Table 1 – Behavior of major CPET variables in several causes of dyspnea
Dyspnea origin
Cardiovascular Pulmonary Vascular-pulmonary Hyperventilation Fake
Variables
VO2 reduced reduced reduced normal reduced
AT early normal early normal normal
R normal reduced normal/reduced normal/reduced reduced
VE/VCO2 slope high high high high normal
PETCO2 low low low at AT low at AT normal
VE/MVV normal reduced normal normal normal
O2 pulse reduced/plateau normal/plateau reduced/plateau normal normal
O2 Sat normal drop drop normal normal
ΔVO2/ΔWR reduced/plateau normal/plateau reduced/plateau normal normal
VO2: oxygen consumption; AT: anaerobic threshold; R: respiratory exchange ratio; VE/VCO2 slope: ratio between pulmonary ventilation and carbon dioxide production; 
PETCO2: extrapolated end-tidal carbon dioxide tension; VE/MVV: ventilatory reserve; O2 Sat: oxyhemoglobin saturation; ΔVO2/ΔWR: relationship between oxygen 
consumption and workload.
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reduction in tidal volume, indicating that the respiratory 
mechanics has reached its functional limit. Dynamic 
hyperinflation can be observed on CPET when periodic 
analyses of the flow-volume curve occurs with inspiratory 
capacity measured during exercise. That is especially useful 
when symptom intensity and the grade of airway obstruction 
is disproportional.
62 
Exertion-induced bronchospasm
Exertion-induced bronchospasm (EIB) is the acute 
narrowing of airways   resulting from exercise. Its clinical 
manifestations include “chest wheezing”, cough, dyspnea 
or chest pressure usually 5 to 10 minutes after exercise, 
and, less commonly, during exercise. Its diagnosis 
requires a specific protocol with repeated post-exertion 
spirometry, typically at 5, 10 and 15 minutes. A drop 
in FEV1 equal to or greater than 10% as compared 
to that of pre-exertion is diagnosed as EIB.
67 For the 
diagnosis of bronchial hyperreactivity, that test is less 
sensitive than bronchoprovocation challenge tests with 
bronchoconstrictors (methacholine, histamine), being, 
however, more specific for the diagnosis of EIB. 
Early detection of pulmonary vascular disease
In addit ion, CPET has been used to the ear ly 
detection of pulmonary vascular disease. However, the 
pathophysiological aspects of pulmonary hypertension are 
worth considering to understand and interpret the findings 
in the clinical context. 
Pulmonary hypertension is defined as mean pulmonary 
artery pressure (mPAP) equal to or greater than 25 mmHg,
68,69
 
and dyspnea on exertion is usually its earliest symptom. 
The pulmonary circulation has high capacitance, and 
normal mPAP values are frequently observed at the early 
Figure 4 – Flow-volume curves: A) patient without pulmonary disease; B) patient with chronic obstructive pulmonary disease. Note loop displacement to the left with 
overlapping. IC: inspiratory capacity; TPC: total pulmonary capacity, TV: tidal volume.
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stages of pulmonary vascular disease. For an increase 
in mPAP levels at rest to occur, more than 50% of the 
pulmonary circulation needs to be obstructed, resulting in 
a relatively late diagnosis of pulmonary vascular disease.
69,70 
The identification of pulmonary hypertension during 
exertion requires the use of a pulmonary artery catheter for 
direct measurement during exercise. This is part of the invasive 
(or advanced) CPET, available only at a few centers. One 
limitation is that the definition of pulmonary hypertension 
on exertion, mPAP greater than 30 mmHg, is arbitrary,
69,71 
and healthy individuals can reach much higher values.
72 
In addition, there are not enough data to conclude that 
patients with that “abnormal hemodynamics” will progress 
to true pulmonary hypertension at rest. 
CPET can provide information to help the clinician 
suspect pulmonary hypertension when assessing a patient 
with dyspnea of undefined etiology. The VE/VCO2 ratio at 
AT and peak exertion are extremely elevated in patients 
with pulmonary hypertension, higher than that of patients 
with HF and same functional class.
73 In addition, low 
PETCO2 values at the end of expiration, both at rest and 
exercise, were associated with pulmonary hypertension. 
It has been suggested that, in the absence of acute 
hyperventilation (normal R), VE/VCO2 ratio greater than 
37 and PETCO2 below 30 mmHg at AT could indicate 
pulmonary vascular disease. Exceptionally low PETCO2 
values (below 20 mmHg) are uncommon in other diseases 
and increase the suspicion of pulmonary hypertension in 
patients assessed for dyspnea on exertion.
74 
Prognostic assessment in pulmonary hypertension
CPET can be used to assess both the severity of 
pulmonary hypertension in patients with established 
disease and the response to therapy. Studying idiopathic 
pulmonary arterial hypertension, Wensel et al. showed 
that individuals with peak VO2 lower than 10.4 mL.kg
-1.
min-1 and  peak SBP lower than 120 mmHg had worse 
prognosis.
75 The guidelines of the European Society of 
Cardiology
69,70 recommend that peak VO2 values greater 
than 15.0 and lower than 12.0 mL.kg
-1
.min
-1 indicate 
good and bad prognosis, respectively. However, that 
parameter should not be assessed isolated, but be part 
of a comprehensive assessment to determine pulmonary 
hypertension severity. 
In addition, VE/VCO2 ratio at AT and VE/VCO2 slope 
have been associated with pulmonary hypertension 
prognosis, with values equal to or greater than 54 and 
62, respectively, indicating shorter survival.
73 However, 
that relationship seems not to apply to all forms of 
pulmonary hypertension. A more elevated VE/VCO2 
slope was observed in pulmonary hypertension due to 
chronic pulmonary thromboembolism as compared to 
pulmonary arterial hypertension. It is worth noting that, 
in pulmonary hypertension due to chronic pulmonary 
thromboembolism, VE/VCO2 slope did not associate with 
functional class, suggesting no relationship with severity 
and high values at early phases.
76 Another parameter 
associated with the worse survival of patients with 
pulmonary arterial hypertension is the presence, on CPET, 
of signs of right-to-left shunt during exercise.
77 
Figure 4: Flow-volume curves: A) patient without 
pulmonary disease; B) patient with chronic obstructive 
pulmonary disease. Note loop displacement to the left 
with overlapping.
CPET in children and adolescents
In the pediatric population, the use of CPET is similar to 
that of the adult population, but with specific particularities 
related to the childhood universe. Environmental conditions 
should allow children to adapt to the test, therefore enabling 
good performance assessment.78 
CPET has been very useful to assess healthy individuals 
and those with complex congenital heart diseases,79 
allowing the determination of pathophysiological causes 
that limit functional capacity.80 Protocols and ergometers 
(treadmill and cycle ergometer) are selected according to 
the objectives and experience of the laboratories conducting 
the tests. Ramp protocols, however, are currently the most 
often applied.
Comparing the cardiorespiratory responses of healthy 
children with those of healthy young adults, Prado et al.81 
have evidenced lower cardiovascular (evidenced by lower 
O2 pulse) and respiratory (lower PETCO2) efficiencies, 
higher respiratory rate and VE/VO2 at peak exercise and at 
AT level. However, healthy children have higher metabolic 
efficiency (lower R and peak VO2, similar to those of healthy 
young adults).
The literature indicates possible reasons for the 
immaturity of the anaerobic metabolism of children during 
physical exercise, such as lower muscular glycogen levels,82 
reduced activity of phosphofrutokinase-1 83 and of lactate 
dehydrogenase,84 and higher proportion of muscle fibers 
of slow contraction.85
In addition, children with heart diseases usually have 
lower aerobic potency than young adults and children 
without heart diseases.86 Other variables derived from CPET 
are extremely useful to measure the response to exercise. 
OUES indicates systemic and pulmonary perfusion, and 
correlates strongly with peak VO2. In children without 
heart diseases, OUES increases with their development.80 
However, according to the study by Dias et al.,86 in 
congenital heart disease, an association was identified 
between OUES and functional impairment severity in 59 
children in the late postoperative period of congenital 
heart disease correction. Those authors have reported that 
reduced OUES was associated with low peak VO2 (below 
80% of the predicted value) in 90% of the cases, confirming 
the presence of a cardiovascular disorder during exertion.
In addition, ergospirometric assessment has been 
extremely useful in the follow-up of partially or completely 
treated complex congenital heart diseases, as an aid to 
indicate the ideal time for new therapeutic interventions. 
Table 1 shows the performance of children in the late 
postoperative period of several cyanogenic congenital heart 
diseases, such as Fallot tetralogy, transposition of the great 
arteries and single ventricle heart.
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Kempny et al.87 have reported the reference values of the 
major ergospirometric variables of adults with congenital 
heart disease, and have correlated their data with those in 
the literature to guide the recreational, sports and professional 
activities of those individuals.
Thus, the association of cardiovascular variables, such as 
O2 pulse and peak VO2, and ventilatory variables (VE/VCO2 
slope) provides more comprehensive and objective data about 
the true functional capacity of children and adolescents with 
congenital heart disease. We provide major examples: after 
late correction of Fallot tetratogy, evolution with pulmonary 
insufficiency and possible right ventricular dilation and 
dysfunction can indicate exchange or, currently, implantation 
of new prostheses, such as Melody’s.88,89 CPET can indicate 
the best time for intervention, when the morphology of the O2 
pulse curve shows a depression or early plateau, in addition 
to ventilatory inefficiency characterized by high VE/VCO2 
slope values. After late correction of transposition of the great 
arteries according to Mustard’s or Senning’s technique, an 
Table 2 – * Comparison of the ergospirometric performance of children with complex congenital heart disease and healthy ones undergoing 
maximal incremental test
Heart disease
(n = 30)
Normal
(n = 30) p 
Age 11.8 ± 6.2 11.9 ± 6.7 NS
Incremental test performance
Max. velocity (km.h-1)  9.8 ± 3.1 10.9 ± 4.9 0.001
AT velocity (km.h-1) 5.7 ± 1.7 6.9 ± 1.5 0.001
Max. inclination (%) 5.2 ± 4.8 6.1 ± 4.7 0.049
Distance (m) 1091.2 ± 384.1 1262.9 ± 307.1 0.001
Time (min) 8.6 ± 1.5 11.5 ± 2.1 0.001
Cardiovascular
Resting HR (bpm) 71.47 ± 11.3 79.0 ± 12.0 0.042
Peak HR (bpm) 175.9 ± 23.0 185.8 ± 19.7 0.031
Resting SBP (mmHg) 106.8 ± 21.4 106.2 ± 19.0 NS
Delta SBP (mmHg) 36.1 ± 1.1 39.2 ± 0.9 0.001
PEAK O2 Pulse  mL.beat-1 10.4 ± 5.5 13.5 ± 3.6 0.001
AT O2 Pulse mL.beat-1 8.3 ± 5.1 12.5 ±3.2 0.001
OUES  1693.5 ± 761.9 1876.6 ± 564.5 0.0001
OUES/kg 34.1 ± 11.1 46.1 ± 9.2 0.0001
Circul. pow. (mmHg/mL/kg) 1924.0 ± 550 3937.5 ± 1220 0.0001
Metabolic
PEAK VO2  mL.min-1 1021 ± 474.2 1637.40 ± 834.0 0.0001 
PEAK VO2  mL.kg.min-1 31.5 ± 7.2 42.3 ± 7.0 0.0001
VO2 AT  mL.min-1 19.5 ± 4.5 25.9 ± 5.3 0.0001
VO2 AT   mL.min-1 643.4 ± 301.8 1004.2 ± 567.5 0.0001
R (VCO2/VO2) 1.02 ± 0.1 1.04 ± 0.1 NS
PETCO2 mm Hg 30.83 ± 4.5 34.2 ± 4.0 0.0001
Ventilatory and gas exchanges
Peak VE L.min-1 50.4± 22.0 55.2 ± 22.2 0.38
RR (rpm) 61.0 ± 15.2  58.6 ± 10.9 NS
PETCO2 mm Hg 32.83 ± 3.90 34.41 ± 3.29 0.0005
VE/VCO2 slope 41.2 ± 6.40 35.5 ± 4.3 0.0001
O2 Sat (%) 90.9 ± 8.2 97.6 ± 1.2 0.0001
AT: anaerobic threshold; HR: heart rate; peak HR: maximal HR reached; delta SBP: difference between peak and resting systolic blood pressure; OUES: oxygen 
uptake efficiency slope; Circul. pow.: circulatory power; PEAKVO2: oxygen consumption at peak exertion; VO2 AT: oxygen consumption at anaerobic threshold; VE: 
pulmonary ventilation; RR: respiratory rate; O2 Sat (%): oxyhemoglobin saturation (modified from reference 86); NS: non-significant.
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older method, many children show worsening of their metabolic 
efficiency (more reduced peak VO2 and excessive ventilation – 
greater VE/VCO2 slope), which does not occur when submitted 
to Jatene’s surgery, considered the ideal technique. Additionally, 
CPET allows the analysis of gas exchange in other more complex 
congenital heart diseases with pulmonary hypertension, such 
as Eisenmenger’s syndrome.88,89
 CPET has been a valuable complementary resource in the 
follow-up of patients with congenital heart diseases to both 
assess the exercise capacity and indicate the ideal time for new 
therapeutic approaches, providing objective, diagnostic and 
prognostic information on the patient’s true cardiopulmonary 
functional status.
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